Recurrent Osteosarcoma Recruiting Phase 2 Trials for Pazopanib (DB06589)

Also known as: Osteosarcoma recurrent / Osteogenic sarcoma recurrent

IndicationStatusPhase
DBCOND0028757 (Recurrent Osteosarcoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02357810Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone SarcomasTreatment